A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT03129100
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ixekizumab — DRUGAdministered SC
- Placebo — DRUGAdministered SC
Study Details
The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.
Key Dates
- Start date
- May 9, 2017
- Status verified
- May 2022
- Primary completion
- May 26, 2020
- Completion
- May 27, 2021
Study Design
- Enrollment
- 773 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ixekizumab (IXE) 80Q4WParticipants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every four weeks (Q4W).
- Experimental: Ixekizumab (IXE) 80Q2WParticipants received 80 milligram (mg) of Ixekizumab subcutaneously (SC) every two weeks (Q2W).
- Placebo Comparator: PlaceboParticipants received subcutaneous dose of placebo.
Primary Outcome Measure
Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment) [ Time Frame: Week 64 ]
Locations (23)
Find similar trials in Phoenix, AZ
By research site
Arizona Arthritis & Rheumatology Research· Phoenix, AZCare Access Research - Huntington Beach· Huntington Beach, CADesert Medical Advances· Palm Desert, CAArthritis Assoc. & Osteoporosis Ctr of Colorado Springs, LLC· Colorado Springs, COClinical Research Center of CT/NY· Danbury, CTArthritis Rheumatic Disease Specialties· Aventura, FL
Related Studies
- A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)PHASE1 · Recruiting · UCB Biopharma SRL · Santa Monica, California
- A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsPHASE1 · Recruiting · UCB Biopharma SRL · Peoria, Arizona
- Physical Activity Through Health Technology in Axial SpondyloarthritisRecruiting · University of Washington · Seattle, Washington